The extra $320.5m (plus inflation) in medical device user fees the US FDA plans to collect during the five fiscal years beginning in 2018 will help fund several completely new review performance goal categories, upgrades to some existing goals, and a range of structural and process enhancements at the agency.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?